Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

Background The aim of this study was to evaluate the usefulness of the presence of malignant pleural effusion (MPE) as a negative predictor of anti‐PD‐1 antibody efficacy. Methods A retrospective review of patients with advanced or recurrent non‐small cell lung cancer treated with an anti‐PD‐1 antib...

Full description

Bibliographic Details
Main Authors: Ryota Shibaki, Shuji Murakami, Yuki Shinno, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noriko Motoi, Noboru Yamamoto, Yuichiro Ohe
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Thoracic Cancer
Subjects:
Anti‐PD‐1 antibody
malignant pleural effusion
nivolumab
non‐small cell lung cancer
pembrolizumab
Online Access:https://doi.org/10.1111/1759-7714.13004

Internet

https://doi.org/10.1111/1759-7714.13004

Similar Items